Sign In
Buy RCKT
$2.92
+0.0300 (+1.04%)
At Close: Jun 03, 2026
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
07:00am, Thursday, 28'th May 2026
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare
RCKT Stock Down on Q1 Earnings Miss, Kresladi Launch in Focus
12:51pm, Monday, 11'th May 2026
Rocket Pharmaceuticals shares fell after a wider-than-expected Q1 loss as the company focuses on the launch of newly approved gene therapy Kresladi.
Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress
04:00pm, Thursday, 07'th May 2026
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare
Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher
07:00am, Tuesday, 28'th Apr 2026
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare
RCKT Stock Down Despite FDA Nod to Gene Therapy in Rare Disease
01:21pm, Monday, 30'th Mar 2026
Rocket Pharmaceuticals drops despite the FDA's accelerated approval of gene therapy Kresladi in severe leukocyte adhesion deficiency-I, an ultra-rare disease.
Contrasting Foghorn Therapeutics (NASDAQ:FHTX) and Rocket Pharmaceuticals (NASDAQ:RCKT)
02:29am, Sunday, 29'th Mar 2026
Foghorn Therapeutics (NASDAQ: FHTX - Get Free Report) and Rocket Pharmaceuticals (NASDAQ: RCKT - Get Free Report) are both small-cap medical companies, but which is the superior business? We will cont
Rocket Pharmaceuticals, Inc. (RCKT) Discusses FDA Approval of KRESLADI Gene Therapy for Severe Leukocyte Adhesion Deficiency Type 1 Transcript
Rocket Pharmaceuticals secures FDA approval for gene therapy KRESLADI
09:59am, Friday, 27'th Mar 2026
Rocket Pharmaceuticals (NASDAQ:RCKT) announced that the US Food and Drug Administration (FDA) has granted accelerated approval for KRESLADI (marnetegragene autotemcel), the company's gene therapy for
Rocket Pharma shares climb as FDA approves first therapy for deadly childhood disorder
07:27am, Friday, 27'th Mar 2026
Rocket Pharmaceuticals shares jumped 10% on Friday before the bell after the U.S. Food and Drug Administration approved its gene therapy for a rare and often fatal immune disorder in children, m
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with hig
Rocket Pharmaceuticals secures FDA approval for gene therapy KRESLADI
05:56am, Friday, 27'th Mar 2026
Rocket Pharmaceuticals (NASDAQ:RCKT) announced that the US Food and Drug Administration (FDA) has granted accelerated approval for KRESLADI (marnetegragene...
Rocket Pharmaceuticals, Inc. (RCKT) Presents at TD Cowen 46th Annual Health Care Conference Transcript
01:56pm, Friday, 06'th Mar 2026
Rocket Pharmaceuticals, Inc. (RCKT) Presents at TD Cowen 46th Annual Health Care Conference Transcript
RCKT's Q4 Loss Narrower Than Estimated, Pipeline in Focus
01:50pm, Friday, 27'th Feb 2026
Rocket Pharmaceuticals reports narrower-than-estimated Q4 loss. The company provides key updates on its pipeline candidates.
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Average Rating of “Hold” from Analysts
01:58am, Friday, 27'th Feb 2026
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT - Get Free Report) has been given an average recommendation of "Hold" by the seventeen research firms that are presently covering the firm, MarketBeat Rating
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress
04:00pm, Thursday, 26'th Feb 2026
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord
